MIF-Associated Immunosuppressive CAF Remodeling Predicts Poor Prognosis During Lung Adenocarcinoma Progression: A Single-Cell and Multicohort Transcriptomic Study
Abstract
1. Introduction
2. Methods
2.1. Data Collection
2.2. Single-Cell RNA Sequencing Data Processing
2.3. Differential Expression Analysis
2.4. Single-Cell Trajectory Analysis
2.5. SCENIC Analysis
2.6. Assessment of Gene Enrichment Scores
2.7. Cell–Cell Communication Analysis
2.8. Functional Enrichment Analysis
2.9. Machine Learning Model
2.10. Model Generalizability Evaluation
2.11. Survival Analysis
2.12. In Vitro Validation of MIF-Associated Fibroblast Activation
2.13. Quantitative Real-Time PCR
3. Results
3.1. Single-Cell Transcriptional Atlas Reveals Stromal and Immune Remodeling During LUAD Progression
3.2. CAF Subtypes Exhibit Stage-Associated Changes in Composition and Function
3.3. Transcriptional Regulatory Programs Differ Across CAF States
3.4. T-Cell Dysfunction Accompanies Stromal Remodeling in Invasive LUAD
3.5. MIF-Associated Epithelial–CAF Communication Is Increased in Invasive Lesions
3.6. LUAD-Conditioned Medium Induces CD74/CD44 Expression and Fibroblast Activation
3.7. An MIF-Related Prognostic Signature Stratifies Survival Risk in LUAD
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| Abbreviation | Full Name |
| LUAD | Lung adenocarcinoma |
| AAH | Atypical adenomatous hyperplasia |
| AIS | Adenocarcinoma in situ |
| MIA | Minimally invasive adenocarcinoma |
| IA | Invasive adenocarcinoma |
| CAFs | Cancer-associated fibroblasts |
| TME | Tumor microenvironment |
| MIF | Macrophage migration inhibitory factor |
| CT | Computed tomography |
| scRNA-seq | Single-cell RNA sequencing |
| TCGA | The Cancer Genome Atlas |
| GEO | Gene Expression Omnibus |
| UMAP | Uniform manifold approximation and projection |
| TFs | Transcription factors |
| GO | Gene Ontology |
| KEGG | Kyoto Encyclopedia of Genes and Genomes |
| GSVA | Gene Set Variation Analysis |
| ATCC | American Type Culture Collection |
| CM | Conditioned medium |
| MFI | Mean fluorescence intensity |
| Enet | Elastic net |
| GBM | Generalized boosted regression modeling |
| plsRcox | Partial least squares regression for Cox |
| RSF | Random survival forest |
| SuperPC | Supervised principal components |
| SVM | Support vector machine |
| LOOCV | Leave-one-out cross-validation |
| ROC | Receiver operating characteristic |
| AUC | Area under the curve |
References
- Pao, W.; Girard, N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011, 12, 175–180. [Google Scholar] [CrossRef] [PubMed]
- Inamura, K. Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression. Int. J. Mol. Sci. 2018, 19, 1259. [Google Scholar] [CrossRef] [PubMed]
- Rizzo, A.; Santoni, M.; Mollica, V.; Logullo, F.; Rosellini, M.; Marchetti, A.; Faloppi, L.; Battelli, N.; Massari, F. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: The MOUSEION-02 study. Expert Opin. Drug Metab. Toxicol. 2021, 17, 1455–1466. [Google Scholar] [CrossRef] [PubMed]
- Rizzo, A.; Dall’Olio, F.G.; Altimari, A.; Giunchi, F.; Ardizzoni, A. Role of PD-L1 assessment in advanced NSCLC: Does it still matter? Anti-Cancer Drugs 2021, 32, 1084–1085. [Google Scholar] [CrossRef] [PubMed]
- Rizzo, A. Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: A matter of debate. Br. J. Cancer 2022, 127, 1381–1382. [Google Scholar] [CrossRef] [PubMed]
- Guven, D.C.; Erul, E.; Kaygusuz, Y.; Akagunduz, B.; Kilickap, S.; De Luca, R.; Rizzo, A. Immune checkpoint inhibitor-related hearing loss: A systematic review and analysis of individual patient data. Support. Care Cancer 2023, 31, 624. [Google Scholar] [CrossRef] [PubMed]
- Nie, M.; Yao, K.; Zhu, X.; Chen, N.; Xiao, N.; Wang, Y.; Peng, B.; Yao, L.; Li, P.; Zhang, P.; et al. Evolutionary metabolic landscape from preneoplasia to invasive lung adenocarcinoma. Nat. Commun. 2021, 12, 6479. [Google Scholar] [CrossRef] [PubMed]
- Zhang, C.; Zhang, Z.; Zhang, G.; Zhang, Z.; Luo, Y.; Wang, F.; Wang, S.; Che, Y.; Zeng, Q.; Sun, N.; et al. Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. Cancer Lett. 2020, 479, 31–41. [Google Scholar] [CrossRef] [PubMed]
- Hu, X.; Fujimoto, J.; Ying, L.; Fukuoka, J.; Ashizawa, K.; Sun, W.; Reuben, A.; Chow, C.W.; McGranahan, N.; Chen, R.; et al. Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat. Commun. 2019, 10, 2978. [Google Scholar] [CrossRef] [PubMed]
- Luo, H.; Xia, X.; Huang, L.B.; An, H.; Cao, M.; Kim, G.D.; Chen, H.N.; Zhang, W.H.; Shu, Y.; Kong, X.; et al. Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment. Nat. Commun. 2022, 13, 6619. [Google Scholar] [CrossRef] [PubMed]
- Sumaiya, K.; Langford, D.; Natarajaseenivasan, K.; Shanmughapriya, S. Macrophage migration inhibitory factor (MIF): A multifaceted cytokine regulated by genetic and physiological strategies. Pharmacol. Ther. 2022, 233, 108024. [Google Scholar] [CrossRef] [PubMed]
- Nobre, C.C.; de Araújo, J.M.; Fernandes, T.A.; Cobucci, R.N.; Lanza, D.C.; Andrade, V.S.; Fernandes, J.V. Macrophage Migration Inhibitory Factor (MIF): Biological Activities and Relation with Cancer. Pathol. Oncol. Res. 2017, 23, 235–244. [Google Scholar] [CrossRef] [PubMed]
- Yu, Q.; Song, H.; Shi, X.Y.; Zhu, L.; Liang, Y.; Gong, R.N.; Dong, X.W.; Liu, S.L.; Wang, H.Z.; Wang, Y.L.; et al. Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis. Signal Transduct. Target. Ther. 2026, 11, 32. [Google Scholar] [CrossRef] [PubMed]
- Wang, Z.; Li, Z.; Zhou, K.; Wang, C.; Jiang, L.; Zhang, L.; Yang, Y.; Luo, W.; Qiao, W.; Wang, G.; et al. Deciphering cell lineage specification of human lung adenocarcinoma with single-cell RNA sequencing. Nat. Commun. 2021, 12, 6500. [Google Scholar] [CrossRef] [PubMed]
- Okayama, H.; Kohno, T.; Ishii, Y.; Shimada, Y.; Shiraishi, K.; Iwakawa, R.; Furuta, K.; Tsuta, K.; Shibata, T.; Yamamoto, S.; et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 2012, 72, 100–111. [Google Scholar] [CrossRef] [PubMed]
- Der, S.D.; Sykes, J.; Pintilie, M.; Zhu, C.Q.; Strumpf, D.; Liu, N.; Jurisica, I.; Shepherd, F.A.; Tsao, M.S. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. J. Thorac. Oncol. 2014, 9, 59–64. [Google Scholar] [CrossRef] [PubMed]
- McShane, L.M.; Altman, D.G.; Sauerbrei, W.; Taube, S.E.; Gion, M.; Clark, G.M. Reporting recommendations for tumor marker prognostic studies (remark). Exp. Oncol. 2006, 28, 99–105. [Google Scholar] [PubMed]
- Butler, A.; Hoffman, P.; Smibert, P.; Papalexi, E.; Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 2018, 36, 411–420. [Google Scholar] [CrossRef] [PubMed]
- Trapnell, C.; Cacchiarelli, D.; Grimsby, J.; Pokharel, P.; Li, S.; Morse, M.; Lennon, N.J.; Livak, K.J.; Mikkelsen, T.S.; Rinn, J.L. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 2014, 32, 381–386. [Google Scholar] [CrossRef] [PubMed]
- Aibar, S.; González-Blas, C.B.; Moerman, T.; Huynh-Thu, V.A.; Imrichova, H.; Hulselmans, G.; Rambow, F.; Marine, J.C.; Geurts, P.; Aerts, J.; et al. SCENIC: Single-cell regulatory network inference and clustering. Nat. Methods 2017, 14, 1083–1086. [Google Scholar] [CrossRef] [PubMed]
- Charoentong, P.; Finotello, F.; Angelova, M.; Mayer, C.; Efremova, M.; Rieder, D.; Hackl, H.; Trajanoski, Z. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017, 18, 248–262. [Google Scholar] [CrossRef] [PubMed]
- Guo, X.; Zhang, Y.; Zheng, L.; Zheng, C.; Song, J.; Zhang, Q.; Kang, B.; Liu, Z.; Jin, L.; Xing, R.; et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 2018, 24, 978–985. [Google Scholar] [CrossRef] [PubMed]
- Zheng, L.; Qin, S.; Si, W.; Wang, A.; Xing, B.; Gao, R.; Ren, X.; Wang, L.; Wu, X.; Zhang, J.; et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 2021, 374, abe6474. [Google Scholar] [CrossRef] [PubMed]
- Cheng, S.; Li, Z.; Gao, R.; Xing, B.; Gao, Y.; Yang, Y.; Qin, S.; Zhang, L.; Ouyang, H.; Du, P.; et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 2021, 184, 792–809.e23. [Google Scholar] [CrossRef] [PubMed]
- Efremova, M.; Vento-Tormo, M.; Teichmann, S.A.; Vento-Tormo, R. CellPhoneDB: Inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat. Protoc. 2020, 15, 1484–1506. [Google Scholar] [CrossRef] [PubMed]
- Jin, S.; Guerrero-Juarez, C.F.; Zhang, L.; Chang, I.; Ramos, R.; Kuan, C.H.; Myung, P.; Plikus, M.V.; Nie, Q. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 2021, 12, 1088. [Google Scholar] [CrossRef] [PubMed]
- Wu, T.; Hu, E.; Xu, S.; Chen, M.; Guo, P.; Dai, Z.; Feng, T.; Zhou, L.; Tang, W.; Zhan, L.; et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation 2021, 2, 100141. [Google Scholar] [CrossRef] [PubMed]
- Hänzelmann, S.; Castelo, R.; Guinney, J. GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013, 14, 7. [Google Scholar] [CrossRef] [PubMed]
- Liu, Z.; Liu, L.; Weng, S.; Guo, C.; Dang, Q.; Xu, H.; Wang, L.; Lu, T.; Zhang, Y.; Sun, Z.; et al. Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nat. Commun. 2022, 13, 816. [Google Scholar] [CrossRef] [PubMed]
- Biffi, G.; Tuveson, D.A. Diversity and Biology of Cancer-Associated Fibroblasts. Physiol. Rev. 2021, 101, 147–176. [Google Scholar] [CrossRef]
- Tirosh, I.; Izar, B.; Prakadan, S.M.; Wadsworth, M.H., 2nd; Treacy, D.; Trombetta, J.J.; Rotem, A.; Rodman, C.; Lian, C.; Murphy, G.; et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016, 352, 189–196. [Google Scholar] [CrossRef] [PubMed]
- Inamura, K.; Togashi, Y.; Okui, M.; Ninomiya, H.; Hiramatsu, M.; Satoh, Y.; Okumura, S.; Nakagawa, K.; Shimoji, T.; Noda, T.; et al. HOXB2 as a novel prognostic indicator for stage I lung adenocarcinomas. J. Thorac. Oncol. 2007, 2, 802–807. [Google Scholar] [CrossRef] [PubMed]
- Wang, D.; Fu, Z.; Gao, L.; Zeng, J.; Xiang, Y.; Zhou, L.; Tong, X.; Wang, X.Q.; Lu, J. Increased IRF9-STAT2 Signaling Leads to Adaptive Resistance toward Targeted Therapy in Melanoma by Restraining GSDME-Dependent Pyroptosis. J. Investig. Dermatol. 2022, 142, 2476–2487.e9. [Google Scholar] [CrossRef] [PubMed]
- Du, L.; Liu, Y.; Li, C.; Deng, J.; Sang, Y. The interaction between ETS transcription factor family members and microRNAs: A novel approach to cancer therapy. Biomed. Pharmacother. 2022, 150, 113069. [Google Scholar] [CrossRef] [PubMed]
- Rani, A.; Greenlaw, R.; Smith, R.A.; Galustian, C. HES1 in immunity and cancer. Cytokine Growth Factor Rev. 2016, 30, 113–117. [Google Scholar] [CrossRef] [PubMed]
- Lee, M.; Cho, H.J.; Park, K.S.; Jung, H.Y. ELK3 Controls Gastric Cancer Cell Migration and Invasion by Regulating ECM Remodeling-Related Genes. Int. J. Mol. Sci. 2022, 23, 3709. [Google Scholar] [CrossRef] [PubMed]
- Chen, J.; Dang, Y.; Feng, W.; Qiao, C.; Liu, D.; Zhang, T.; Wang, Y.; Tian, D.; Fan, D.; Nie, Y.; et al. SOX18 promotes gastric cancer metastasis through transactivating MCAM and CCL7. Oncogene 2020, 39, 5536–5552. [Google Scholar] [CrossRef] [PubMed]
- Dhanasekaran, R.; Deutzmann, A.; Mahauad-Fernandez, W.D.; Hansen, A.S.; Gouw, A.M.; Felsher, D.W. The MYC oncogene—The grand orchestrator of cancer growth and immune evasion. Nat. Rev. Clin. Oncol. 2022, 19, 23–36. [Google Scholar] [CrossRef] [PubMed]
- Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 2016, 16, 582–598. [Google Scholar] [CrossRef] [PubMed]
- Osipyan, A.; Chen, D.; Dekker, F.J. Epigenetic regulation in macrophage migration inhibitory factor (MIF)-mediated signaling in cancer and inflammation. Drug Discov. Today 2021, 26, 1728–1734. [Google Scholar] [CrossRef] [PubMed]
- Youness, R.A.; Elemam, N.M.; Abdelhamid, A.M.; Mohamed, A.H.; Elsherbiny, L.M.; Ramzy, A.; Assal, R.A. Macrophage migration inhibitory factor (MIF) and the tumor ecosystem: A tale of inflammation, immune escape, and tumor growth. Front. Immunol. 2025, 16, 1636839. [Google Scholar] [CrossRef] [PubMed]
- Xie, W.; Dong, Y.; Lv, J.; Wang, X. Macrophage migration inhibitory factor superfamily in tumor metabolism: Mechanistic insights and therapeutic potential. Biochem. Pharmacol. 2026, 246, 117720. [Google Scholar] [CrossRef] [PubMed]
- Özdemir, B.C.; Pentcheva-Hoang, T.; Carstens, J.L.; Zheng, X.; Wu, C.C.; Simpson, T.R.; Laklai, H.; Sugimoto, H.; Kahlert, C.; Novitskiy, S.V.; et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014, 25, 719–734. [Google Scholar] [CrossRef] [PubMed]





Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Lin, G.; Ji, J.; Ge, F.; Hui, Z. MIF-Associated Immunosuppressive CAF Remodeling Predicts Poor Prognosis During Lung Adenocarcinoma Progression: A Single-Cell and Multicohort Transcriptomic Study. Biomedicines 2026, 14, 1581. https://doi.org/10.3390/biomedicines14071581
Lin G, Ji J, Ge F, Hui Z. MIF-Associated Immunosuppressive CAF Remodeling Predicts Poor Prognosis During Lung Adenocarcinoma Progression: A Single-Cell and Multicohort Transcriptomic Study. Biomedicines. 2026; 14(7):1581. https://doi.org/10.3390/biomedicines14071581
Chicago/Turabian StyleLin, Guo, Jianrui Ji, Fan Ge, and Zhouguang Hui. 2026. "MIF-Associated Immunosuppressive CAF Remodeling Predicts Poor Prognosis During Lung Adenocarcinoma Progression: A Single-Cell and Multicohort Transcriptomic Study" Biomedicines 14, no. 7: 1581. https://doi.org/10.3390/biomedicines14071581
APA StyleLin, G., Ji, J., Ge, F., & Hui, Z. (2026). MIF-Associated Immunosuppressive CAF Remodeling Predicts Poor Prognosis During Lung Adenocarcinoma Progression: A Single-Cell and Multicohort Transcriptomic Study. Biomedicines, 14(7), 1581. https://doi.org/10.3390/biomedicines14071581

